import type { MatrixCountrySlug } from '@/data/industryMarketResearchMatrix';
import type { ServiceLandingExpandedContent } from '@/data/serviceLandingContent';

export type HealthcareIndustryExpandedContent = ServiceLandingExpandedContent & {
  execution: { heading: string; paragraphs: string[] };
};

const healthcareDeliverables = [
  'Executive summary mapped to one hospital, payer, or provider-network decision',
  'Stakeholder segmentation with influence and objection themes by channel',
  'Quantitative sizing or adoption metrics where the objective requires measurement',
  'Qualitative depth modules for pathway, procurement, and patient-flow questions',
  '30/60/90 action plan with owners and evidence gaps flagged',
  'Audit-ready methodology appendix for internal review or partner diligence',
];

const EGYPT_REGULATORY: string[] = [
  'Healthcare provider research in Egypt must reflect EDA oversight for pharmaceutical adjacency, UHIA and public procurement rhythms for hospital supply, and the split between Ministry of Health facilities, university hospitals, and private chains—not a single “national hospital average.”',
  'Institutional formulary and tender cycles differ between Cairo corridors and Upper Egypt networks; evidence programs map where decisions actually occur before field scales.',
  'Ethics committee and hospital permissions apply when research includes clinician depth interviews or operational workflow observation; BioNixus scopes feasibility before recruitment calendars lock.',
  'Arabic–English execution is standard for physician, nurse, and administrator interviews so nuance in patient flow and procurement language is preserved for global sponsors.',
  'Cross-MENA harmonization helps regional portfolios, but Egypt-specific channel mix and payer behaviour require local primary research rather than imported GCC averages.',
  'Hospital accreditation, quality metrics, and service-line expansion plans increasingly shape administrator priorities; research should capture operational KPIs alongside clinical adoption when medtech or specialty care is in scope.',
  'Seasonal demand spikes (Ramadan staffing, summer expatriate flows) can shift outpatient volumes; tracking studies should document field windows so conclusions are not attributed to structural change.',
];

const UAE_REGULATORY: string[] = [
  'Healthcare provider research in the UAE spans MOHAP federal oversight, DHA licensing in Dubai, and DOH Abu Dhabi pathways—each with distinct hospital networks, insurance density, and procurement cadence.',
  'Dual-licensing and Emirates Drug Establishment (EDE) pricing evolution affect how hospitals source pharmaceuticals and devices; provider research should trace procurement and formulary influence alongside clinical adoption.',
  'Private hospital growth, medical tourism, and employer-sponsored insurance create channel diversity that syndicated trackers rarely segment cleanly; local mixed-method design is required.',
  'Arabic–English fieldwork preserves nuance in administrator, clinician, and payer conversations while maintaining comparable analytics for regional leadership.',
  'Cross-emirate benchmarking (Dubai, Abu Dhabi, Northern Emirates) prevents conclusions that over-weight a single hospital cluster.',
  'Employer-sponsored insurance and self-pay segments create distinct patient flows; provider research should tag payer type before sizing service-line opportunity.',
  'Medical tourism and resident care pathways diverge for elective specialties; feasibility confirms which cohorts are in scope for the decision objective.',
];

const SAUDI_REGULATORY: string[] = [
  'Healthcare provider research in Saudi Arabia must align with SFDA context where therapies intersect hospital formularies, NUPCO procurement overlays for institutional supply, and Vision 2030 privatization of provider networks.',
  'Concentrated hospital groups and ministry facilities follow different committee rhythms; evidence programs map institutional sequencing before field investment scales.',
  'SFDA Economic Evaluation System requirements increasingly shape how hospitals evaluate high-cost therapies; provider research should surface committee narratives that dossiers alone miss.',
  'Arabic–English moderation is standard for administrator, physician, and pharmacy stakeholder depth across public and private channels.',
  'Saudi cells within GCC programs roll up cleanly while preserving local institutional decision points in readouts.',
  'Privatization under Vision 2030 introduces new hospital operators with distinct formulary culture; landscape modules should refresh annually for active portfolios.',
  'Digital health and telemedicine adoption vary by cluster; provider research can include workflow modules when remote monitoring affects service-line economics.',
];

const GCC_MARKET_SNIPPET =
  'The GCC pharmaceutical market was worth roughly USD 23.7 billion in 2024 and is projected to reach about USD 49 billion by 2033 — a 7.6% CAGR (BioNixus market analysis, 2024).';

export const HEALTHCARE_INDUSTRY_EXPANDED: Record<MatrixCountrySlug, HealthcareIndustryExpandedContent> = {
  egypt: {
    hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
    regulatory: {
      heading: 'Regulatory and institutional context for Egypt healthcare provider research',
      paragraphs: EGYPT_REGULATORY,
    },
    marketContext: {
      heading: 'Why Egypt hospital and provider research requires channel-aware evidence',
      paragraphs: [
        `${GCC_MARKET_SNIPPET} Egypt’s large population and mixed public–private provider landscape make channel segmentation essential—Cairo elite private networks behave differently from ministry facilities and Upper Egypt referral patterns.`,
        'Hospital procurement, UHIA listing dynamics, and out-of-pocket segments coexist; provider research must trace where patients enter care and how institutions source therapies and devices.',
        'Multinational medtech and pharma teams often run Egypt as a MENA anchor cell; BioNixus harmonizes instruments while preserving Egypt-specific channel readouts for medical and commercial leadership.',
        'Launch and expansion decisions fail when prescriber enthusiasm is mistaken for institutional uptake; provider research links clinical intent to formulary, tender, and workflow constraints.',
        'Egypt’s pharmaceutical manufacturing base means many hospitals source locally while still navigating imported specialty therapies; provider modules should trace dual sourcing and substitution behaviour where relevant.',
        'Administrator interviews often reveal bed-capacity and staffing constraints that limit service-line expansion even when clinical demand exists—insights commercial teams miss when research stops at physician panels.',
        'BioNixus pairs Egypt provider research with the Egypt healthcare market report and Egypt pharmaceutical company page when sponsors need macro context alongside institutional depth.',
      ],
    },
    services: {
      heading: 'Healthcare provider market research services BioNixus delivers in Egypt',
      items: [
        {
          title: 'Hospital and network landscape mapping',
          description:
            'Identify influential provider groups, referral cascades, and procurement nodes across public, university, and private channels.',
        },
        {
          title: 'Physician and administrator depth interviews',
          description:
            'Arabic–English qual modules for pathway, formulary, and operational workflow questions with audit-ready transcripts.',
        },
        {
          title: 'Quantitative provider and payer surveys',
          description:
            'Segmentation, adoption metrics, and tracking with channel-tagged quotas and documented exclusion rules.',
        },
        {
          title: 'Patient-flow and service-line sizing',
          description:
            'Bottom-up models linking diagnosed populations to treating centres rather than desk epidemiology alone.',
        },
        {
          title: 'Procurement and tender intelligence',
          description:
            'Structured modules where UHIA or institutional tender dynamics shape uptake for devices or hospital-supplied therapies.',
        },
        {
          title: 'GCC and MENA roll-up from Egypt cell',
          description:
            'Comparable metrics with Saudi and UAE appendices for regional portfolio committees.',
        },
      ],
    },
    methodology: {
      heading: 'Egypt healthcare provider research methodology',
      paragraphs: [
        'Objective lock to one provider-network or hospital-system decision before instrument design prevents unfocused stakeholder lists.',
        'Channel quotas reflect therapy-specific public versus private mix assumptions validated during feasibility—not post-hoc weighting.',
        'Mixed-method sequencing pairs qual depth with quant validation so leadership receives one evidence framework.',
        'Every engagement includes a 30/60/90 action roadmap linked to institutional and commercial timelines.',
        'Audit-ready appendices document recruitment, exclusion logs, and limitation statements for medical affairs review.',
        'Soft-launch QC and daily field telemetry catch channel drift before database lock—especially when public and private completes must stay balanced.',
        'Workshop readouts include named owners for each recommendation so hospital strategy teams can execute without re-scoping the study.',
      ],
    },
    useCases: {
      heading: 'Common Egypt healthcare provider research use cases',
      paragraph:
        'Egypt provider research peaks when hospital network strategy, service-line expansion, or institutional access requires local evidence.',
      areas: [
        'Hospital network prioritisation',
        'Service-line and specialty expansion',
        'Device and medtech pathway mapping',
        'Formulary and procurement barrier diagnosis',
        'Competitive provider landscaping',
        'Patient-flow and referral optimisation',
      ],
    },
    process: {
      heading: 'How BioNixus runs Egypt healthcare provider programs',
      steps: [
        {
          title: 'Decision and channel scoping',
          body: 'Align on one outcome—network entry, service growth, or access barrier removal—and map public, private, and university channels.',
        },
        {
          title: 'Feasibility and ethics alignment',
          body: 'Validate sample reach, permissions, and bilingual instrument requirements before field opens.',
        },
        {
          title: 'Field execution with daily QC',
          body: 'Recruit administrators, clinicians, and pharmacy stakeholders with channel telemetry and soft-launch checks.',
        },
        {
          title: 'Integrated analysis and readout',
          body: 'Deliver objection libraries, sizing outputs, and executive synthesis in one workshop-ready pack.',
        },
      ],
    },
    deliverables: { heading: 'Typical Egypt healthcare provider deliverables', bullets: healthcareDeliverables },
    decisionBlueprint: {
      why: 'Hospital and provider decisions in Egypt concentrate in identifiable networks and procurement rhythms—generic syndication misses the committees that gate uptake.',
      evidence:
        'Mixed-method programs with channel-tagged quotas, Arabic–English depth, and procurement-aware modules surface institutional behaviour prescriber panels alone cannot.',
      next: 'Scope a focused Egypt cell aligned to one network or service-line decision, then extend to GCC benchmarking if the portfolio requires comparable readouts.',
    },
    faqs: [
      {
        question: 'Does BioNixus cover both Cairo and regional Egypt provider networks?',
        answer:
          'Yes. Feasibility maps Cairo, Alexandria, and Upper Egypt reach where therapy models require it, with channel tags so analysis does not over-weight capital-city completes.',
      },
      {
        question: 'Can Egypt healthcare provider research link to pharmaceutical fieldwork?',
        answer:
          'Yes. Provider modules integrate with Egypt pharma fieldwork and the Egypt pharmaceutical company page when launch planning spans hospital and community channels.',
      },
      {
        question: 'How long does Egypt healthcare provider feasibility take?',
        answer:
          'Focused feasibility typically completes within five to ten business days; multi-channel hospital scopes or regional Upper Egypt cells may require longer institution mapping before recruitment opens.',
      },
      {
        question: 'Does BioNixus run mixed-method provider programs in Egypt?',
        answer:
          'Yes. Qual depth and quant validation share one evidence framework with channel-tagged quotas, Arabic–English moderation, and audit-ready appendices suitable for medical affairs review.',
      },
      {
        question: 'Can Egypt provider research benchmark against GCC markets?',
        answer:
          'Yes. Egypt cells harmonize instruments with Saudi and UAE modules so regional leadership receives comparable metrics while preserving Egypt-specific public–private readouts.',
      },
      {
        question: 'What deliverables accompany Egypt hospital network studies?',
        answer:
          'Typical packs include executive synthesis, stakeholder maps, objection libraries, sizing outputs where required, 30/60/90 actions with named owners, and methodology appendices documenting recruitment and exclusions.',
      },
      {
        question: 'How does BioNixus handle UHIA and tender context in Egypt?',
        answer:
          'Where institutional procurement shapes uptake, BioNixus adds tender- and pharmacy-aware modules alongside administrator interviews so access teams understand listing and substitution behaviour—not prescriber intent alone.',
      },
      {
        question: 'When should Egypt provider research refresh institutional maps?',
        answer:
          'BioNixus recommends refresh before major tender windows, hospital network mergers, or service-line expansions—typically annually for active portfolios and quarterly when UHIA or ministry procurement rules shift. Stakeholder maps with channel tags let teams re-field only the segments that changed rather than repeating full national scopes.',
      },
    ],
    execution: {
      heading: 'From Egypt provider insight to network and access alignment',
      paragraphs: [
        'Provider research earns its budget when it changes which hospital networks you prioritize, how administrators sequence service-line investment, and where procurement friction will delay uptake—not when Cairo physician enthusiasm is mistaken for national adoption. BioNixus links readouts to explicit gates: which public facilities can absorb training spend before tender windows close, which private chains require administrator depth before clinician scale-up, and which Upper Egypt referral paths need separate evidence packs.',
        'Execution planning should pair with Egypt pharmaceutical market research, pharma fieldwork Egypt, and the healthcare market research hub so medical, access, and commercial teams synchronize on channel maps before field investment scales across ministry, university, and private quotas.',
        'Workshop deliverables include institution priority tiers, procurement risk registers, and bilingual objection libraries administrators and clinicians can validate—reducing rework when global decks arrive without Egypt channel nuance.',
        'When portfolios include medtech or specialty care, administrator modules capture bed-capacity, staffing, and capital expenditure gates that determine whether service-line expansion proceeds even when clinical demand is visible in physician interviews alone.',
        'Regional sponsors should review Cairo versus Upper Egypt completes separately in workshop readouts; BioNixus flags channel skew before sign-off so network prioritization reflects treatable demand where facilities can operationalize change.',
      ],
    },
  },
  uae: {
    hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
    regulatory: {
      heading: 'Regulatory and institutional context for UAE healthcare provider research',
      paragraphs: UAE_REGULATORY,
    },
    marketContext: {
      heading: 'Why UAE hospital and provider research requires emirate-level evidence',
      paragraphs: [
        `${GCC_MARKET_SNIPPET} The UAE combines high private-hospital density, employer-sponsored insurance, and medical tourism—segments that behave differently from ministry-led markets.`,
        'DHA, DOH, and MOHAP pathways create parallel licensing and procurement logic; provider research must segment emirates and payer types before conclusions roll up.',
        'Specialty hospital clusters (oncology, cardiac, fertility, aesthetics) concentrate influence; broad physician lists without institution tags distort segment strategy.',
        'BioNixus links provider evidence to MOHAP and access context where therapy models require it, with bilingual execution standard across MENA programs.',
        'Insurance prior-authorization and co-pay structures shape uptake for specialty care; payer-administrator modules clarify where friction sits in the patient journey.',
        'Hospital group mergers and new greenfield facilities shift referral patterns quickly; landscape refresh cadence should match active launch timelines.',
        'For pharmaceutical adjacency, pair this page with UAE pharmaceutical market research and the UAE healthcare market report when decisions span provider and drug channels.',
      ],
    },
    services: {
      heading: 'Healthcare provider market research services BioNixus delivers in the UAE',
      items: [
        {
          title: 'Emirate and payer segmentation studies',
          description:
            'Quant and qual modules tagged by Dubai, Abu Dhabi, and Northern Emirates with insurance and channel splits.',
        },
        {
          title: 'Private hospital network mapping',
          description:
            'Identify influential groups, referral pathways, and service-line decision nodes for medtech and specialty care.',
        },
        {
          title: 'Administrator and clinician depth interviews',
          description:
            'Arabic–English qual for formulary, procurement, and patient-flow questions with medical terminology QA.',
        },
        {
          title: 'Medical tourism and expatriate cohort modules',
          description:
            'Where relevant, segment resident versus visitor care pathways so sizing reflects treatable populations.',
        },
        {
          title: 'Competitive provider landscaping',
          description:
            'Neutral mapping of incumbent service lines, capacity, and positioning by emirate and payer type.',
        },
        {
          title: 'GCC roll-up from UAE cell',
          description:
            'Harmonized instruments with Saudi and Kuwait appendices for regional portfolio decisions.',
        },
      ],
    },
    methodology: {
      heading: 'UAE healthcare provider research methodology',
      paragraphs: [
        'Emirate and payer quotas are set during feasibility—not adjusted after field—to prevent Dubai skew.',
        'Institution verification precedes clinician recruitment when influence concentrates in named hospital groups.',
        'Message and objection coding uses pre-specified frameworks comparable across GCC cells.',
        'Deliverables include 30/60/90 actions with named owners for medical, access, and commercial teams.',
        'Methodology appendices document bilingual QC, exclusion rules, and limitation statements.',
        'Soft-launch completes validate emirate quotas before full field opens; daily telemetry flags payer or institution skew early.',
        'Workshop readouts separate emirate appendices from GCC roll-up slides so local teams receive actionable detail without averaging away Dubai–Abu Dhabi differences.',
        'Workshop cadence includes pre-field alignment on emirate and payer tags, a mid-field telemetry review, and a final readout where Dubai, Abu Dhabi, and Northern Emirates cells are validated before 30/60/90 actions are assigned.',
      ],
    },
    useCases: {
      heading: 'Common UAE healthcare provider research use cases',
      paragraph:
        'UAE provider research supports hospital network strategy, specialty service expansion, and institutional access planning.',
      areas: [
        'Private hospital entry and expansion',
        'Specialty service-line growth',
        'Insurance and payer narrative testing',
        'Medtech pathway and procurement mapping',
        'Competitive provider positioning',
        'Cross-emirate benchmarking',
      ],
    },
    process: {
      heading: 'How BioNixus runs UAE healthcare provider programs',
      steps: [
        {
          title: 'Emirate and payer scoping',
          body: 'Define decision objective and segment Dubai, Abu Dhabi, and other emirates with payer tags.',
        },
        {
          title: 'Institution-led feasibility',
          body: 'Validate hospital network reach and administrator access before clinician scale-up.',
        },
        {
          title: 'Bilingual field execution',
          body: 'Run Arabic–English instruments with daily QC and channel telemetry.',
        },
        {
          title: 'Executive synthesis',
          body: 'Integrate qual and quant into one readout with GCC optional appendices.',
        },
      ],
    },
    deliverables: { heading: 'Typical UAE healthcare provider deliverables', bullets: healthcareDeliverables },
    decisionBlueprint: {
      why: 'UAE provider decisions split across emirates, payers, and private networks—averaging the market hides the institutions that gate uptake.',
      evidence:
        'Emirate-tagged mixed-method research with administrator and clinician depth surfaces procurement and pathway behaviour syndicated data misses.',
      next: 'Scope a UAE cell on one service-line or network decision, then extend to Saudi or Egypt comparators if the portfolio requires regional roll-up.',
    },
    faqs: [
      {
        question: 'Does BioNixus segment Dubai and Abu Dhabi provider research?',
        answer:
          'Yes. Quotas and analysis tags distinguish DHA, DOH, and MOHAP contexts so readouts reflect emirate-specific institutional behaviour.',
      },
      {
        question: 'Can UAE healthcare provider studies include payer and insurer modules?',
        answer:
          'Yes. Where decisions depend on insurance policy or employer sponsorship, BioNixus adds payer depth alongside hospital administrator interviews.',
      },
      {
        question: 'How does BioNixus avoid Dubai skew in UAE provider research?',
        answer:
          'Emirate and payer quotas are locked during feasibility with soft-launch QC; daily telemetry flags institution or insurance skew before database lock so Abu Dhabi and Northern Emirates voices stay represented.',
      },
      {
        question: 'Can UAE provider research support medtech and device launches?',
        answer:
          'Yes. Service-line and procurement modules trace hospital committee behaviour, prior authorization, and workflow constraints that device adoption depends on beyond clinical enthusiasm.',
      },
      {
        question: 'Does BioNixus offer Arabic fieldwork for UAE hospital administrators?',
        answer:
          'Yes. Arabic–English instruments and moderation are standard; medical terminology is reviewed with local advisors before field so nuance is preserved for global sponsors.',
      },
      {
        question: 'Can UAE healthcare provider studies roll up to GCC benchmarks?',
        answer:
          'Yes. UAE cells use harmonized instruments with Saudi and Kuwait appendices so regional portfolio committees receive comparable metrics without losing emirate-specific detail.',
      },
      {
        question: 'What timeline should teams expect for UAE provider programs?',
        answer:
          'Focused qual modules often field within three to five weeks after feasibility; larger multi-emirate quant programs may extend depending on institution access and payer recruitment requirements.',
      },
      {
        question: 'How does BioNixus validate insurer and payer quotas in UAE provider studies?',
        answer:
          'Feasibility defines employer-sponsored, government, and self-pay targets by emirate; soft-launch completes are reviewed against quota tables before database lock. Daily telemetry flags over-representation of Dubai private insurers or under-representation of Northern Emirates facilities, triggering corrective recruitment without delaying the full readout timeline.',
      },
      {
        question: 'Can UAE provider research inform medical tourism positioning separate from resident care?',
        answer:
          'Yes. Visitor and resident cohorts receive separate analysis tags so elective service-line sizing reflects sustainable domestic demand. Administrator modules document referral partnerships and international patient coordinators where tourism pathways differ from employer-sponsored insurance workflows in Dubai and Abu Dhabi clusters.',
      },
    ],
    execution: {
      heading: 'From UAE provider insight to emirate and payer alignment',
      paragraphs: [
        'UAE provider research changes outcomes when it clarifies which emirate and payer segments justify launch sequencing, where prior authorization will compress adoption, and which hospital groups concentrate influence for your service line. BioNixus ties scenarios to gates: Dubai private growth versus Abu Dhabi insurance density, medical tourism cohorts versus resident care pathways, and administrator-led procurement rhythms that physician panels alone cannot surface.',
        'Pair UAE execution with UAE pharmaceutical market research, pharma fieldwork UAE, and the healthcare market research hub so brand, medical, and access teams align on institutional behaviour before multi-emirate field spend scales.',
        'Deliverables include emirate-tagged influence maps, payer friction summaries, and 30/60/90 actions with named owners so hospital strategy and access teams execute without re-scoping after the readout workshop.',
        'Medical tourism and resident cohorts receive separate tags in analysis so sizing and messaging recommendations do not treat visitor volumes as sustainable domestic demand for elective service lines.',
        'Portfolio teams should treat emirate-level readouts as the default decision unit: roll-up summaries follow validated Dubai, Abu Dhabi, and Northern Emirates cells rather than collapsing the market into a single national index. BioNixus documents payer friction, prior-authorization rules, and hospital group influence separately so access and medical education investments align to the institutions that gate uptake in each emirate.',
      ],
    },
  },
  'saudi-arabia': {
    hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
    regulatory: {
      heading: 'Regulatory and institutional context for Saudi Arabia healthcare provider research',
      paragraphs: SAUDI_REGULATORY,
    },
    marketContext: {
      heading: 'Why Saudi hospital and provider research requires institutional sequencing',
      paragraphs: [
        `${GCC_MARKET_SNIPPET} Saudi Arabia accounts for a large share of GCC spend; provider research must reflect ministry facilities, privatizing hospital groups, and NUPCO overlays where institutional procurement shapes uptake.`,
        'Vision 2030 healthcare investment concentrates specialty capacity in named clusters; influence mapping beats undifferentiated physician panels.',
        'SFDA EES and formulary committee narratives increasingly determine high-cost therapy access; provider research surfaces objections dossiers miss.',
        'BioNixus executes bilingual programs with audit-ready governance suitable for multinational medical and access teams.',
        'Cluster cities (Riyadh, Jeddah, Dammam) concentrate specialty capacity; quotas should reflect where patients actually receive advanced care.',
        'Pharmacist substitution and institutional protocols can override physician preference; provider research documents operational rules committees rely on.',
        'Connect Saudi provider modules with HEOR consulting and pharma fieldwork Saudi Arabia when launch planning spans hospital, payer, and community channels.',
      ],
    },
    services: {
      heading: 'Healthcare provider market research services BioNixus delivers in Saudi Arabia',
      items: [
        {
          title: 'Hospital group and ministry network mapping',
          description:
            'Identify institutional decision nodes across public, privatized, and specialty clusters.',
        },
        {
          title: 'Formulary and committee objection research',
          description:
            'Qual modules for P&T, medical affairs, and administrator perspectives on listing and sequencing.',
        },
        {
          title: 'Quantitative provider adoption surveys',
          description:
            'Segmentation and tracking with institution tags and documented QC.',
        },
        {
          title: 'NUPCO and procurement overlay modules',
          description:
            'Where institutional supply shapes uptake, trace tender and substitution behaviour alongside clinical research.',
        },
        {
          title: 'Specialty centre and referral pathway studies',
          description:
            'Map concentrated treatment nodes for oncology, cardiac, metabolic, and rare-disease portfolios.',
        },
        {
          title: 'GCC roll-up from Saudi cell',
          description:
            'Comparable metrics with UAE and Kuwait appendices for regional leadership.',
        },
      ],
    },
    methodology: {
      heading: 'Saudi Arabia healthcare provider research methodology',
      paragraphs: [
        'Decision lock to one institutional or network outcome before stakeholder lists expand.',
        'Institution verification and committee calendar mapping precede recruitment when listing windows are time-bound.',
        'Arabic–English instruments with medical terminology review preserve nuance for global sponsors.',
        'Mixed-method integration delivers one evidence pack for medical, access, and commercial teams.',
        'Audit-ready appendices support internal review and partner diligence.',
        'Committee calendar alignment precedes payer recruitment when listing windows are narrow; feasibility documents institutional rhythms before calendars lock.',
        'Saudi readouts tag ministry, privatized, and specialty-cluster completes so analysis reflects Vision 2030 network diversity rather than a single Riyadh skew.',
        'Workshop cadence includes pre-field alignment on institution tags, a mid-field telemetry review, and a final readout where cluster segments are validated before 30/60/90 actions are assigned—preventing global teams from acting on undifferentiated Saudi averages.',
      ],
    },
    useCases: {
      heading: 'Common Saudi Arabia healthcare provider research use cases',
      paragraph:
        'Saudi provider research supports hospital network strategy, formulary defence, and specialty service expansion under Vision 2030.',
      areas: [
        'Hospital group prioritisation',
        'Formulary and committee objection mapping',
        'Specialty centre influence mapping',
        'NUPCO and procurement intelligence',
        'Private-sector expansion planning',
        'Regional GCC benchmarking',
      ],
    },
    process: {
      heading: 'How BioNixus runs Saudi Arabia healthcare provider programs',
      steps: [
        {
          title: 'Institutional scoping',
          body: 'Align on network, formulary, or service-line decision and map ministry versus private pathways.',
        },
        {
          title: 'Feasibility and permissions',
          body: 'Validate hospital access, committee timing, and bilingual requirements.',
        },
        {
          title: 'Field with institution tags',
          body: 'Recruit administrators, clinicians, and pharmacy leaders with daily QC.',
        },
        {
          title: 'Access-aligned readout',
          body: 'Link findings to SFDA and payer context with 30/60/90 actions for launch teams.',
        },
      ],
    },
    deliverables: {
      heading: 'Typical Saudi Arabia healthcare provider deliverables',
      bullets: healthcareDeliverables,
    },
    decisionBlueprint: {
      why: 'Saudi provider decisions concentrate in identifiable hospital groups and committee rhythms—syndicated averages hide the gates that determine uptake.',
      evidence:
        'Institution-tagged mixed-method research with formulary and procurement modules surfaces behaviour prescriber-only panels cannot.',
      next: 'Scope a Saudi cell on one network or formulary decision, then harmonize with UAE or Egypt cells if the portfolio requires GCC roll-up.',
    },
    faqs: [
      {
        question: 'Does Saudi healthcare provider research account for NUPCO procurement?',
        answer:
          'Where institutional supply shapes uptake, BioNixus adds procurement-aware modules alongside clinician and administrator depth interviews.',
      },
      {
        question: 'Can provider research connect to SFDA EES planning?',
        answer:
          'Yes. When high-cost therapies face economic evaluation, provider modules surface committee narratives that inform HEOR and access dossiers before submission.',
      },
      {
        question: 'Does BioNixus map Saudi hospital groups and specialty clusters?',
        answer:
          'Yes. Landscape modules identify ministry, privatized, and specialty-centre nodes with institution tags so field and medical plans align to concentrated treatment networks.',
      },
      {
        question: 'Can Saudi provider research include pharmacist and administrator depth?',
        answer:
          'Yes. Formulary and substitution behaviour often sits with pharmacy and operations leaders; BioNixus recruits across roles with documented exclusion rules and bilingual QC.',
      },
      {
        question: 'How does BioNixus align Saudi provider research with Vision 2030 privatization?',
        answer:
          'Feasibility refreshes hospital operator lists as new groups enter the market; readouts tag operator type so conclusions are not anchored to legacy ministry behaviour alone.',
      },
      {
        question: 'Can Saudi healthcare provider modules integrate with pharma fieldwork?',
        answer:
          'Yes. Provider evidence pairs with pharma fieldwork Saudi Arabia and HEOR consulting when launch planning spans hospital, payer, and community channels under SFDA context.',
      },
      {
        question: 'What governance artefacts accompany Saudi provider studies?',
        answer:
          'Sponsors receive audit-ready appendices, channel telemetry, soft-launch notes, Arabic transcripts with terminology QA, and 30/60/90 action plans with named owners for access and medical teams.',
      },
      {
        question: 'How does BioNixus prevent Riyadh skew in Saudi provider research?',
        answer:
          'Feasibility sets ministry, privatized, and specialty-cluster quotas across Riyadh, Jeddah, and Eastern Province cells; soft-launch completes are checked against institution tags before database lock. Daily telemetry flags geographic or operator skew so corrective recruitment preserves Vision 2030 network diversity in the final readout.',
      },
      {
        question: 'Can Saudi provider research support specialty-centre launch sequencing?',
        answer:
          'Yes. Cluster maps identify concentrated treatment nodes for oncology, cardiac, metabolic, and rare-disease portfolios; administrator and committee modules document referral pathways and formulary gates that determine whether a centre can operationalize a new service line even when specialist demand is visible in physician interviews alone.',
      },
    ],
    execution: {
      heading: 'From Saudi provider insight to formulary and cluster alignment',
      paragraphs: [
        'Saudi provider research earns its budget when it reshapes which hospital clusters and formulary committees you prioritize, how NUPCO or institutional procurement overlays adoption, and when medical education should precede access submissions under SFDA Economic Evaluation System expectations—not when specialist enthusiasm is treated as national uptake.',
        'BioNixus connects execution readouts to HEOR consulting Saudi Arabia, pharma fieldwork Saudi Arabia, and the healthcare market research hub so medical, access, and field teams synchronize on ministry versus privatized network maps before scale-up across Riyadh, Jeddah, and Eastern Province cells.',
        'Final packs include cluster-level centre maps, formulary objection themes, and committee calendar notes so access submissions and medical education investments align to the institutional gates that actually determine uptake.',
        'Privatized operator entry under Vision 2030 means landscape modules should refresh as new hospital groups launch; BioNixus documents operator type in quotas so legacy ministry behaviour is not mistaken for the full market.',
        'Portfolio committees should review cluster-level readouts before national roll-up: ministry, privatized, and specialty-centre segments receive separate 30/60/90 actions so access submissions and field plans align to the institutional gates that determine uptake in each network—not a single Riyadh-weighted average.',
      ],
    },
  },
};

export function getHealthcareIndustryExpandedContent(
  countrySlug: MatrixCountrySlug,
): HealthcareIndustryExpandedContent | null {
  return HEALTHCARE_INDUSTRY_EXPANDED[countrySlug] ?? null;
}
